中断治疗的 HIV 治愈相关临床试验中，预防暴露前用药对降低 HIV 传播风险的作用
Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.
机构信息
Vaccine Research Institute, Université Paris Est Créteil.
INSERM U955, équipe 16, Faculté de Médecine, Université Paris Est Créteil.
出版信息
J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S16-S18. doi: 10.1093/infdis/jiz036.
Abstract
Analytical treatment interruption performed during human immunodeficiency virus (HIV) cure-related clinical trials exposes sex partners of participants in these trials to a risk of HIV transmission. Preexposure prophylaxis (PrEP), which emerged in recent years as a key strategy for preventing HIV transmission, is often considered a useful tool to prevent this risk. This article supports offering PrEP to the stable sex partners of participants in these trials but also notes limitations that must be addressed. It concludes that PrEP cannot on its own eliminate the risk of secondary transmission in this context.
摘要
在与 HIV 治愈相关的临床试验中进行的分析性治疗中断，会使这些试验参与者的性伴侣面临 HIV 传播的风险。暴露前预防（PrEP）是近年来出现的预防 HIV 传播的关键策略之一，通常被认为是预防这种风险的有用工具。本文支持为这些试验参与者的稳定性伴侣提供 PrEP，但也指出了必须解决的局限性。它得出结论认为，PrEP 本身并不能消除这种情况下二次传播的风险。
相似文献
1
Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.中断治疗的 HIV 治愈相关临床试验中，预防暴露前用药对降低 HIV 传播风险的作用
J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S16-S18. doi: 10.1093/infdis/jiz036.
2
Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate.在一项治疗性疫苗候选物研究中，一名性伴侣意外感染 HIV-1。
J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S5-S6. doi: 10.1093/infdis/jiz012.
3
Is it ethical to isolate study participants to prevent HIV transmission during trials with an analytical treatment interruption?在分析性治疗中断试验中，为了防止艾滋病毒传播而将研究参与者隔离开来，这样做是否合乎伦理？
J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S19-S21. doi: 10.1093/infdis/jiz164.
4
Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?我们应该担心替诺福韦/恩曲他滨暴露前预防产生的耐药性吗？
Curr Opin HIV AIDS. 2016 Jan;11(1):49-55. doi: 10.1097/COH.0000000000000209.
5
Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.用于预防艾滋病病毒的暴露前预防：安全性问题。
Drug Saf. 2017 Apr;40(4):273-283. doi: 10.1007/s40264-017-0505-6.
6
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.HIV 暴露前预防在跨性别女性中的应用：iPrEx 试验的亚组分析。
Lancet HIV. 2015 Dec;2(12):e512-9. doi: 10.1016/S2352-3018(15)00206-4. Epub 2015 Nov 6.
7
Perceptions of HIV Preexposure Prophylaxis Among Young Pregnant Women from Rural KwaZulu-Natal, South Africa.南非夸祖鲁-纳塔尔省农村地区年轻孕妇对 HIV 暴露前预防的认知。
AIDS Patient Care STDS. 2019 May;33(5):214-219. doi: 10.1089/apc.2018.0242.
8
The Pre-Exposure Prophylaxis-Stigma Paradox: Learning from Canada's First Wave of PrEP Users.暴露前预防-污名悖论：从加拿大第一批 PrEP 用户中吸取经验教训。
AIDS Patient Care STDS. 2018 Jan;32(1):24-30. doi: 10.1089/apc.2017.0153. Epub 2017 Nov 29.
9
Removing One Barrier to Protecting Sex Partners in HIV Remission Studies With a Treatment Interruption.消除 HIV 缓解研究中断治疗时保护性伴侣的一个障碍。
J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S22-S23. doi: 10.1093/infdis/jiz162.
10
How to Address the Risk of HIV Transmission in Remission Studies With Treatment Interruption: The Low-Hanging Fruit Approach.如何解决中断治疗缓解期研究中 HIV 传播的风险：低挂果实方法。
J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S7-S11. doi: 10.1093/infdis/jiz163.
引用本文的文献
1
Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment Interruption.早期病毒动力学可预测分析性治疗中断后人类免疫缺陷病毒的治疗后控制情况。
J Infect Dis. 2025 Feb 20;231(2):e419-e428. doi: 10.1093/infdis/jiae551.
2
Understanding participant perspectives around HIV-1 cure-related studies involving antiretroviral analytical treatment interruptions in the United Kingdom.了解英国围绕涉及抗逆转录病毒分析性治疗中断的HIV-1治愈相关研究的参与者观点。
J Virus Erad. 2023 Dec 15;9(4):100360. doi: 10.1016/j.jve.2023.100360. eCollection 2023 Dec.
3
A partner protection package for HIV cure-related trials involving analytical treatment interruptions.涉及分析性治疗中断的 HIV 治愈相关试验的合作伙伴保护方案。
Lancet Infect Dis. 2023 Oct;23(10):e418-e430. doi: 10.1016/S1473-3099(23)00267-0. Epub 2023 Jun 6.
4
Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design.平衡 HIV 治愈临床试验设计中的统计功效和风险。
J Infect Dis. 2022 Aug 24;226(2):236-245. doi: 10.1093/infdis/jiac032.
5
Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection.涉及急性 HIV 感染期诊断的 HIV 缓解临床研究的伦理考虑。
BMC Med Ethics. 2021 Dec 28;22(1):169. doi: 10.1186/s12910-021-00716-1.
6
Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.HIV 治愈相关研究中分析治疗中断期间降低性伴侣风险的伦理和实践考虑因素。
HIV Res Clin Pract. 2021 Feb;22(1):14-30. doi: 10.1080/25787489.2021.1902116. Epub 2021 Mar 24.
7
8
Characterization of Physicians That Might Be Reluctant to Propose HIV Cure-Related Clinical Trials with Treatment Interruption to Their Patients? The ANRS-APSEC Study.可能不愿向患者提议开展与中断治疗相关的HIV治愈临床试验的医生特征？ANRS-APSEC研究。
Vaccines (Basel). 2020 Jun 23;8(2):334. doi: 10.3390/vaccines8020334.
9
Applying the Behavioural and Social Sciences Research (BSSR) Functional Framework to HIV Cure Research.将行为和社会科学研究（BSSR）功能框架应用于 HIV 治愈研究。
J Int AIDS Soc. 2019 Oct;22(10):e25404. doi: 10.1002/jia2.25404.
10
Secondary HIV Infection and Mitigation in Cure-Related HIV Trials During Analytical Treatment Interruptions.治疗中断期间治愈相关HIV试验中的继发性HIV感染与缓解
J Infect Dis. 2019 Aug 30;220(7):1230-1231. doi: 10.1093/infdis/jiz262.
本文引用的文献
1
Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate.在一项治疗性疫苗候选物研究中，一名性伴侣意外感染 HIV-1。
J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S5-S6. doi: 10.1093/infdis/jiz012.
2
Lessons learned from HIV antiretroviral treatment interruption trials.从 HIV 抗逆转录病毒治疗中断试验中吸取的教训。
Curr Opin HIV AIDS. 2018 Sep;13(5):416-421. doi: 10.1097/COH.0000000000000484.
3
Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa.权衡口服暴露前预防药物对南部非洲女性预防艾滋病毒有效性的证据
AIDS Res Hum Retroviruses. 2018 Aug;34(8):645-656. doi: 10.1089/AID.2018.0031. Epub 2018 Jun 19.
4
Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.暴露前预防用药时高浓度替诺福韦二磷酸酯体内浓度的患者获得野生型 HIV-1 感染：病例报告。
Lancet HIV. 2017 Nov;4(11):e522-e528. doi: 10.1016/S2352-3018(17)30132-7. Epub 2017 Sep 14.
5
Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.用于预防艾滋病病毒的暴露前预防：安全性问题。
Drug Saf. 2017 Apr;40(4):273-283. doi: 10.1007/s40264-017-0505-6.
6
Pre-exposure prophylaxis: a useful tool to prevent human immunodeficiency virus infection?暴露前预防：预防人类免疫缺陷病毒感染的有效工具？
Clin Microbiol Infect. 2016 Sep;22(9):757-767. doi: 10.1016/j.cmi.2016.08.029. Epub 2016 Sep 8.
7
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.按需暴露前预防治疗在 HIV-1 感染高危男性中的应用。
N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1.
8
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.暴露前预防以预防HIV-1感染（PROUD）：一项实用开放标签随机试验试点阶段的有效性结果
Lancet. 2016 Jan 2;387(10013):53-60. doi: 10.1016/S0140-6736(15)00056-2. Epub 2015 Sep 9.
9
Tenofovir-based preexposure prophylaxis for HIV infection among African women.基于替诺福韦的暴露前预防用于非洲女性的HIV感染
N Engl J Med. 2015 Feb 5;372(6):509-18. doi: 10.1056/NEJMoa1402269.
10
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.单药替诺福韦与恩曲他滨联合替诺福韦用于HIV-1暴露前预防：一项随机、双盲、3期试验数据的更新
Lancet Infect Dis. 2014 Nov;14(11):1055-1064. doi: 10.1016/S1473-3099(14)70937-5. Epub 2014 Oct 7.
Zotero 插件